	US 11,752,122 B2
	N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling
Jasimuddin Ahamed, Edmond, OK (US)
Assigned to Oklahoma Medical Research Foundation, Oklahoma City, OK (US)
Appl. No. 15/733,422
Filed by OKLAHOMA MEDICAL RESEARCH FOUNDATION, Oklahoma City, OK (US)
PCT Filed Feb. 1, 2019, PCT No. PCT/US2019/016231 § 371(c)(1), (2) Date Jul. 24, 2020, PCT Pub. No. WO2019/152765, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/625,652, filed on Feb. 2, 2018.
Prior Publication US 2021/0093599 A1, Apr. 1, 2021
Int. Cl. A61K 31/198 (2006.01); A61P 9/00 (2006.01); A61B 17/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/198 (2013.01) [A61B 17/00 (2013.01); A61K 45/06 (2013.01); A61P 9/00 (2018.01); A61B 2017/00243 (2013.01); A61B 2017/00783 (2013.01)]

18 Claims

1. A method of treating aortic valve stenosis in a human subject comprising administering to said subject N-acetylecysteine (NAC) at about 0.01 to 4 g of NAC per kg per day.